Article
Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.
Annals of hematology - 23 Feb 2026
Kawano Mana, Kunimoto Hiroyoshi, Izumi Akihiko, Adachi Akiko, Miura Ayaka, Yokoyama Chiaki, Hasegawa Kodai, Shirafuta Mayoko, Tanaka Marika, Sakuma Takayuki, Ohashi Takuma, Takahashi Hiroyuki, Miyazaki Takuya, Tachibana Takayoshi, Hagihara Maki, Matsumoto Kenji, Nakajima Hideaki
Abstract excerpt
Donor cell-derived myelodysplastic syndrome/acute myeloid leukemia is a rare but serious complication of allogeneic hematopoietic stem cell transplantation, and its optimal treatment has not been established. Here, we report a case of a 44-year-old woman who was diagnosed with donor cell-derived...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Pyrazines
- Aniline Compounds
- Female
- Myelodysplastic Syndromes
- Adult
- Mutation
- Hematopoietic Stem Cell Transplantation
- Male
- Recurrence
- Protein Kinase Inhibitors